| Petros Pharmaceuticals, Inc. (PTPI) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q2-CY2026 | Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | |
| Balance Sheet Date | 2025-Dec-31 | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2023-Sep-30 | 2023-Jun-30 | 2023-Mar-31 | 2022-Dec-31 | 2022-Sep-30 | 2022-Jun-30 | 2022-Mar-31 | 2021-Dec-31 | 2021-Sep-30 | 2021-Jun-30 | 2021-Mar-31 | |||||||||||||||||||||||||||||
| Fiscal Period | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q1-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | |||||||||||||||||||||||||||||
| Operating Cash Flow | (933,544$) | (1,133,924$) | (3,007,151$) | (1,660,088$) | 965,405$ | (771,246$) | (1,662,362$) | (1,134,848$) | (2,259,894$) | (4,046,202$) | (572,070$) | (748,363$) | (1,570,340$) | (1,751,476$) | (4,199,808$) | (5,275,701$) | (8,304,299$) | (1,211,366$) | (1,899,785$) | (446,581$) | (4,522,895$) | (2,667,119$) | (5,740,044$) | (2,375,267$) | |||||||||||||||||||||||||
| Investing Cash Flow | (5,449$) | 0$ | (204$) | 0$ | (4,429$) | ||||||||||||||||||||||||||||||||||||||||||||
| Purchases of Property and Equipment | 5,449$ | 0$ | 204$ | 0$ | 4,429$ | ||||||||||||||||||||||||||||||||||||||||||||
| Financing Cash Flow | 0$ | (117,311$) | (428,233$) | 8,707,002$ | (1,144,670$) | (2,774,945$) | (1,958,340$) | (1,121,411$) | (2,373,080$) | 14,631,354$ | (363,201$) | (357,833$) | (185,058$) | (361,951$) | (176,974$) | (900,000$) | 24,016,687$ | (1,684,627$) | (1,635,748$) | (2,126,403$) | 20,993,514$ | 2,504,635$ | 5,429,965$ | 1,375,726$ | |||||||||||||||||||||||||
| End Cash Position | 5,136,722$ | 6,070,266$ | 7,321,501$ | 8,931,054$ | 1,718,645$ | 3,900,000$ | 7,500,000$ | 11,100,000$ | 13,336,975$ | 18,000,000$ | 7,400,000$ | 8,300,000$ | 9,426,264$ | 11,200,000$ | 13,295,089$ | 17,671,871$ | 23,847,572$ | 8,135,184$ | 11,031,177$ | 14,566,710$ | 17,139,694$ | 669,075$ | 831,763$ | 1,141,845$ | |||||||||||||||||||||||||
| Exchange Rate Effect | |||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends Paid | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unlevered Free Cash Flow | (933,544$) | (1,133,924$) | (3,007,151$) | (1,660,088$) | 959,956$ | (771,246$) | (1,662,362$) | (1,134,848$) | (2,259,894$) | (4,046,202$) | (572,070$) | (748,363$) | (1,570,340$) | (1,751,476$) | (4,199,808$) | (5,275,701$) | (8,304,299$) | (1,211,366$) | (1,899,785$) | (446,581$) | (4,522,895$) | (2,667,323$) | (5,740,044$) | (2,379,696$) | |||||||||||||||||||||||||